Dr. Daver on the Next Steps for Menin Inhibitors in AML
In Partnership With:
Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.
Naval Daver, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps for menin inhibitors in acute myeloid leukemia (AML).
Optimization of the management of differentiation syndrome (DS) is needed in AML because DS has been seen more frequently and at higher potency compared with what has previously been seen with other therapies, such as IDH inhibitors, Daver explains. Another important step is to move menininhibitors into combination regimens to be used early in the disease course. This could spare the patient years of single-agent therapy in a space where almost all targeted therapies perform better when combined with other agents, Daver adds.
Ultimately, a critical step is to have several menin inhibitors approved for use in AML, Daver continues. Although menin inhibitors are associated with some toxicities, they also construe more power for differentiation, which makes it possible to optimize and individualize treatment, Daver concludes.
